Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Mineralys Therapeutics Inc MLYS.OQ reported a quarterly adjusted loss of $1.13​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -57 cents. The mean expectation of seven analysts for the quarter was for a loss of 83 cents per share. Wall Street expected results to range from -93 cents to -66 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Mineralys Therapeutics Inc's reported EPS for the quarter was a loss of $1.13​.

• The company reported a quarterly loss of $56.34 million.

• Mineralys Therapeutics Inc shares had risen by 15.9% this quarter and gained 63.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Mineralys Therapeutics Inc is 31.00

This summary was machine generated from LSEG data November 12 at 03:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)